Related Experiment Video

Updated: Jun 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeted therapies and autophagy: new insights from chronic myeloid leukemia

Paolo Salomoni1, Bruno Calabretta

  • 1MRC Toxicology Unit, University of Leicester, Leicester, UK. ps90@le.ac.uk

Autophagy
|August 29, 2009
PubMed

Insights

Inhibiting autophagy can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) in eradicating chronic myeloid leukemia (CML) stem cells. This approach targets CML cells that survive TKI treatment, improving therapeutic outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Chronic myeloid leukemia (CML) is often treated with tyrosine kinase inhibitors (TKIs) targeting the BCR/Abl oncogene.
  • While TKIs induce apoptosis in most CML cells, resistant stem cells and advanced-phase cells survive, leading to disease recurrence.
  • Understanding mechanisms of TKI resistance and CML stem cell survival is crucial for developing more effective treatments.

Purpose of the Study:

  • To investigate the role of autophagy in CML cell survival during TKI treatment.
  • To determine if inhibiting autophagy can enhance TKI efficacy against CML stem cells.

Main Methods:

  • Exposure of CML cells, including stem cells, to TKIs.
  • Analysis of autophagic program activation in response to TKIs.
  • Pharmacological and RNAi-mediated inhibition of autophagy.
  • Assessment of TKI-induced cell death potentiation by autophagy inhibition.

Main Results:

  • CML cells, including stem cells, activate an autophagic program upon TKI exposure.
  • This autophagy relies on intracellular calcium and is Bcl-2 independent.
  • Inhibiting autophagy pharmacologically or via RNAi significantly enhances TKI-induced death in CML cells, including stem cells.

Conclusions:

  • Autophagy inhibition is a promising strategy to improve TKI therapy for CML.
  • Targeting autophagy may overcome TKI resistance mechanisms in CML stem cells.
  • Autophagy represents a key stress response in cancer cells, particularly upon oncogenic signaling abrogation.

More Related Videos

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry11:39

Assessing Autophagic Flux by Measuring LC3, p62, and LAMP1 Co-localization Using Multispectral Imaging Flow Cytometry

Published on: July 21, 2017

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
Delivery Pathways to the Lysosome01:36

Delivery Pathways to the Lysosome

Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...